Citadel Advisors LLC acquired a new position in shares of Vital Therapies (NASDAQ:VTL) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 38,569 shares of the company’s stock, valued at approximately $229,000. Citadel Advisors LLC owned approximately 0.09% of Vital Therapies as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds also recently bought and sold shares of the company. Victory Capital Management Inc. raised its holdings in Vital Therapies by 12.4% in the 4th quarter. Victory Capital Management Inc. now owns 2,925,886 shares of the company’s stock valued at $17,409,000 after acquiring an additional 322,797 shares in the last quarter. BlackRock Inc. increased its stake in shares of Vital Therapies by 136.2% in the 4th quarter. BlackRock Inc. now owns 990,828 shares of the company’s stock valued at $5,896,000 after purchasing an additional 571,418 shares during the last quarter. Granahan Investment Management Inc. MA increased its stake in shares of Vital Therapies by 51.4% in the 3rd quarter. Granahan Investment Management Inc. MA now owns 388,282 shares of the company’s stock valued at $1,961,000 after purchasing an additional 131,828 shares during the last quarter. Dowling & Yahnke LLC bought a new position in shares of Vital Therapies in the 3rd quarter valued at $252,000. Finally, New York State Common Retirement Fund bought a new position in shares of Vital Therapies in the 3rd quarter valued at $213,000. Hedge funds and other institutional investors own 25.99% of the company’s stock.
NASDAQ VTL traded down $0.50 on Friday, hitting $5.95. 245,923 shares of the stock traded hands, compared to its average volume of 185,556. Vital Therapies has a 12 month low of $2.25 and a 12 month high of $7.30. The firm has a market cap of $273.28, a price-to-earnings ratio of -4.54 and a beta of 4.26.
Vital Therapies (NASDAQ:VTL) last posted its earnings results on Tuesday, March 13th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.04). During the same period in the previous year, the firm posted ($0.37) earnings per share. equities research analysts anticipate that Vital Therapies will post -1.35 earnings per share for the current fiscal year.
VTL has been the topic of a number of analyst reports. BidaskClub raised Vital Therapies from a “sell” rating to a “hold” rating in a research note on Wednesday, January 31st. Zacks Investment Research downgraded Vital Therapies from a “hold” rating to a “sell” rating in a research note on Saturday, March 17th. Finally, ValuEngine raised Vital Therapies from a “strong sell” rating to a “sell” rating in a research note on Wednesday, March 28th.
COPYRIGHT VIOLATION WARNING: “Citadel Advisors LLC Takes $229,000 Position in Vital Therapies (VTL)” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright legislation. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/04/07/citadel-advisors-llc-acquires-shares-of-38569-vital-therapies-inc-vtl.html.
Vital Therapies Profile
Vital Therapies, Inc, a biotherapeutic company, focuses on developing a human hepatic cell-based therapy targeting the treatment of acute forms of liver failure in the United States. Its ELAD system is an extracorporeal human allogeneic cellular liver therapy that is in Phase III clinical trials to allow the patient's own liver to potentially regenerate to a healthy state or to stabilize the patient until transplant.
Receive News & Ratings for Vital Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies and related companies with MarketBeat.com's FREE daily email newsletter.